Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | GBA1 | P04062 | 1/20 | 0.32 |
| ▸ | PDE4A | P27815 | 3/20 | 0.31 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.31 |
| ▸ | PDE4C | Q08493 | 3/20 | 0.31 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.31 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.31 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19117256 | 0.94 | GBA1 (0.32) | MAPTL3MBTL1MEN1KMT2AGBA1 | |
| SCHEMBL20737985 | 0.88 | GBA1 (0.48) | ALDH1A1GBA1 | |
| SCHEMBL19101570 | 0.88 | CYP3A4 (0.38) | MAPTL3MBTL1MEN1KMT2AALDH1A1 | |
| SCHEMBL22899043 | 0.87 | GAA (0.43) | MAPTL3MBTL1MEN1KMT2AALDH1A1 | |
| SCHEMBL18891644 | 0.87 | L3MBTL1 (0.36) | MAPTL3MBTL1MEN1KMT2AALDH1A1 | |
| SCHEMBL18562455 | 0.83 | TP53 (0.33) | — | |
| SCHEMBL22899076 | 0.83 | F2 (0.43) | MAPTL3MBTL1MEN1KMT2AALDH1A1 | |
| SCHEMBL22898914 | 0.81 | PDE4A (0.33) | GBA1PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL22898915 | 0.81 | PDE4A (0.33) | GBA1PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL20990325 | 0.80 | F2 (0.40) | MAPTL3MBTL1MEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220402091-A1 | METHOD AND APPARATUS FOR FORMING POROUS ADVANCED POLISHING PADS USING AN ADDITIVE MANUFACTURING PROCESS | APPLIED MATERIALS, INC. | 2022-12-22 | — | — | US | disclosed |
| US-11296357-B2 | Non-aqueous electrolytic solution and non-aqueous electrolyte secondary battery using the same | MITSUBISHI CHEMICAL CORPORATION (JP) | 2022-04-05 | — | — | US | disclosed |
| US-20210020991-A1 | NONAQUEOUS ELECTROLYTE SOLUTION AND NONAQUEOUS ELECTROLYTE BATTERY | MITSUBISHI CHEMICAL CORPORATION (JP) | 2021-01-21 | — | — | US | disclosed |
| US-10615455-B2 | Non-aqueous electrolytic solution and non-aqueous electrolyte secondary battery using the same | MITSUBISHI CHEMICAL CORPORATION (JP) | 2020-04-07 | — | — | US | disclosed |
| US-20200036041-A1 | NON-AQUEOUS ELECTROLYTIC SOLUTION AND NON-AQUEOUS ELECTROLYTE SECONDARY BATTERY USING THE SAME | MITSUBISHI CHEMICAL CORPORATION (JP) | 2020-01-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210020991-A1 | NONAQUEOUS ELECTROLYTE SOLUTION AND NONAQUEOUS ELECTROLYTE BATTERY | SLC9B2, SLC9A1, SLC9A2 | MAPT 3672/4885L3MBTL1 4142/4885MEN1 1906/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.